A 6-hydroxydopamine in vivo model of parkinson's disease

20Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Animal models of Parkinson's disease are essential to explore pathophysiological hypotheses and to test new treatment options, including neurotrophic factors. Catecholaminergic neurotoxins used to generate such models are 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. These neurotoxins predominantly kill dopaminergic neurons through oxidative damage and mitochondrial failure, although 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine fails to induce a significant dopaminergic neurodegeneration in rats. The present chapter describes a protocol for the 6-hydroxydopamine rat model based on stereotaxic injection performed only unilaterally, which mimics an early-to-mid stage of the disease. © 2012 Springer Science+Business Media, LLC.

Cite

CITATION STYLE

APA

Mercanti, G., Bazzu, G., & Giusti, P. (2012). A 6-hydroxydopamine in vivo model of parkinson’s disease. Methods in Molecular Biology, 846, 355–364. https://doi.org/10.1007/978-1-61779-536-7_30

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free